Therapeutic Efficacy of177Lu-Labeled A20FMDV2 Peptides Targeting ανβ6

Truc Thao Huynh, Sreeja Sreekumar, Cedric Mpoy, Buck Edward Rogers

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Integrin ανβ6 promotes migration and invasion of cancer cells, and its overexpression often correlates with poor survival. Therefore, targeting ανβ6 with radioactive peptides would be beneficial for cancer imaging and therapy. Previous studies have successfully developed radiotracers based on the peptide A20FMDV2 that showed good binding specificity for ανβ6 . However, one concern of these ανβ6 integrin-targeting probes is that their rapid blood clearance and low tumor uptake would preclude them from being used for therapeutic purposes. In this study, albumin binders were used to increase tumor uptake for therapeutic applications while the non-albumin peptide was evaluated as a potential positron emission tomography (PET) imaging agent. All peptides used the DOTA chelator for radiolabeling with either68Ga for imaging or177Lu for therapy. PET imaging with [68Ga]Ga-DOTA-(PEG28)2-A20FMDV2 revealed specific tumor uptake in ανβ6-positive tumors. Albumin-binding peptides EB-DOTA-(PEG28)2-A20FMDV2 and IBA-DOTA-(PEG28)2-A20FMDV2 were radiolabeled with177Lu. Biodistribution studies in normal mice showed longer blood circulation times for the albumin binding peptides compared to the non-albumin peptide. Therapy studies in mice demonstrated that both177Lu-labeled albumin binding peptides resulted in significant tumor growth inhibition. We believe these are the first studies to demonstrate the therapeutic efficacy of a radiolabeled peptide targeting an ανβ6-positive tumor.

Original languageEnglish
Article number229
Issue number2
StatePublished - Feb 2022


  • Albumin binder
  • Integrin αβ
  • Theranostics


Dive into the research topics of 'Therapeutic Efficacy of177Lu-Labeled A20FMDV2 Peptides Targeting ανβ6'. Together they form a unique fingerprint.

Cite this